Promedior Announces Presentation of Preclinical Data at AASLD Demonstrating that Pentraxin-2 Suppresses Liver Fibrosis

Published: Nov 02, 2011

MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA. The data to be presented highlight the efficacy and utility of Pentraxin-2 in suppressing fibrosis and providing a clear hepatoprotective effect in independent models of liver fibrosis. In liver fibrosis, Pentraxin-2 inhibits the activation of monocytes, fibrocytes and hepatic stellate cells. Promedior’s lead product, PRM-151, is a recombinant form of the naturally circulating human protein Pentraxin-2, which has been shown to regulate the cell populations that control fibrosis, inflammation and pathologic neovascularization.

Back to news